Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates

Publisher Website
Google Scholar
Abstract
Meropenem, a new broad-spectrum carbapenem antibiotic, demonstrated excellent in vitro activity against major respiratory pathogens includingMoraxella catarrhalis, Haemophilus influenzae andStreptococcus pneumoniae. Minimal inhibitory concentrations of meropenem forMoraxella catarrhalis andHaemophilus influenzae isolates were frequently less than those of imipenem. For nosocomial amikacin-resistant gram-negative bacilli, meropenem had eightfold lower MIC90 values compared to imipenem against strains ofSerratia marcescens, Enterobacter cloacae andEscherichia coli; it was 32-fold more active than imipenem againstProteus mirabilis isolates. Activity was similar to that of imipenem againstPseudomonas aeruginosa isolates. Overall, meropenem showed excellent activity against common community-acquired pathogens as well as amikacin-resistant nosocomial pathogens.